Hormonal
Vagus nerve stimulation (VNS) and GLP-1 analogs are emerging therapeutic tools that harness brain-body communication to treat obesity and diabetes, though more invasive and long-lasting approaches are needed.
If lifestyle changes are insufficient, medical interventions like GLP-1 analogs (e.g., semaglutide) and vagus nerve stimulation are proven to help reverse metabolic disease by targeting brain-body signals. These are powerful tools, but they may be invasive or expensive. Work with your healthcare provider to determine if these options are appropriate for your specific situation, keeping in mind that more accessible long-term solutions are still being developed.
The recent development of GLP1 analogs such as semaglutide and the refinement of vagus nerve stimulation approaches shows that harnessing the ability to control body–brain signals is crucial to reverse metabolic disease [32,78].
Why this rating
The paper cites specific drugs (semaglutide) and procedures (VNS) with established clinical evidence, though it calls for more economical and long-lasting approaches.
Source
Brain–body communication in metabolic control
Alessandro Furlan et al. · Trends in Endocrinology and Metabolism · 2023
DOI 10.1016/j.tem.2023.08.014
More from this paper
- Physical activity improves metabolic health and reduces blood glucose levels independently of weight loss and insulin signaling pathways.Good
- Obesity and metabolic disease are driven by a misalignment between behaviors (feeding/fasting rhythms, physical activity) and tissue functions (organ clocks), regulated by circadian molecular clocks in the brain and periphery.Good
- Brown adipose tissue (BAT) activation and the 'browning' of white adipose tissue (WAT) represent a potential therapeutic avenue for increasing energy expenditure and reducing body weight, although its clinical relevance in humans remains debated.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →